Renal function, P-gp-affecting drugs and new anticoagulants for stroke prevention

International Journal of Cardiology

Volumn 168, Issue 1, 2013, Pages 576-577

  Höllerl, Florian ^a   Stöllberger, Claudia ^a   Finsterer, Josef ^a  

^a KRANKENANSTALT RUDOLFSTIFTUNG   (Austria)

Author keywords

Anticoagulation; Atrial fibrillation; Renal failure

Indexed keywords

ALPHA TOCOPHEROL; AMIODARONE; ANTICOAGULANT AGENT; CARVEDILOL; CLARITHROMYCIN; DABIGATRAN ETEXILATE; DILTIAZEM; DIPYRIDAMOLE; GLYCOPROTEIN P INHIBITOR; MULTIDRUG RESISTANCE PROTEIN; PROPRANOLOL; SIMVASTATIN; VERAPAMIL;

ADULT; AGED; BLADDER BLEEDING; BLEEDING; CEREBROVASCULAR ACCIDENT; CHADS2 SCORE; COMORBIDITY; CONTROLLED STUDY; CREATININE CLEARANCE; CROSS-SECTIONAL STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG POTENTIATION; EPISTAXIS; FEMALE; GENE; GLOMERULUS FILTRATION RATE; HEART ATRIUM FIBRILLATION; HEMOPERITONEUM; HOSPITALIZATION; HUMAN; KIDNEY FUNCTION; LETTER; MAJOR CLINICAL STUDY; MALE; MDR1 GENE; PERICARDIAL EFFUSION; PREVALENCE; PRIORITY JOURNAL; RECTUM HEMORRHAGE; RETROPERITONEAL HEMORRHAGE; RETROSPECTIVE STUDY;

ANTICOAGULATION; ATRIAL FIBRILLATION; RENAL FAILURE;

AGED; AGED, 80 AND OVER; ANTICOAGULANTS; BENZIMIDAZOLES; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; KIDNEY; MALE; MIDDLE AGED; P-GLYCOPROTEIN; PYRIDINES; RETROSPECTIVE STUDIES; STROKE;

EID: 84883781619     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2013.01.013     Document Type: Article

References (10)

1. S.J. Connolly, M.D. Ezekowitz, and S. Yusuf Dabigatran versus warfarin in patients with atrial fibrillation N Engl J Med 361 2009 1139 1151
2. M.R. Patel, K.W. Mahaffey, and J. Garg Rivaroxaban versus warfarin in nonvalvular atrial fibrillation N Engl J Med 365 2011 883 891
3. L. Jungbauer, C. Dobias, C. Stöllberger, and F. Weidinger The frequency of prescription of P-glycoprotein-affecting drugs in atrial fibrillation J Thromb Haemost 8 2010 2069 2070
4. K.M. Jönsson, M. Wieloch, and G. Sterner Glomerular filtration rate in patients with atrial fibrillation on warfarin treatment: a subgroup analysis from the AURICULA registry in Sweden Thromb Res 128 2011 341 345
5. E.L. Cano, and M.A. Miyares Clinical challenges in a patient with dabigatran-induced fatal hemorrhage Am J Geriatr Pharmacother 10 2012 160 163
6. C. Stöllberger, S. Rakusan, F.T. Wimpissinger, and J. Finsterer Spontaneous gross haematuria during dabigatran therapy for secondary stroke prevention Thromb Haemost 108 2012 579 581
7. M. Legrand, J. Mateo, and A. Aribaud The use of dabigatran in elderly patients Arch Intern Med 171 2011 1285 1286
8. C.A. Barton, W.D. McMillian, S.S. Raza, and R.E. Keller Hemopericardium in a patient treated with dabigatran etexilate Pharmacotherapy 32 2012 e103 e107
9. A. Lillo-Le Louët, M. Wolf, and L. Soufir Life-threatening bleeding in four patients with an unusual excessive response to dabigatran: implications for emergency surgery and resuscitation Thromb Haemost 108 2012 583 585
10. K.H. Liesenfeld, T. Lehr, C. Dansirikul, P.A. Reilly, S.J. Connolly, and M.D. Ezekowitz Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non-valvular atrial fibrillation from the RE-LY trial J Thromb Haemost 9 2011 2168 2175